Results 111 to 120 of about 295,397 (306)

Epidermal Interferon‐κ Drives Cutaneous Lupus‐Like Lesions, Photosensitivity, and Systemic Autoimmunity In Vivo

open access: yesArthritis &Rheumatology, EarlyView.
Objective Keratinocyte‐derived interferon (IFN) κ is chronically overexpressed in human nonlesional systemic lupus erythematosus (SLE) skin. Recent evidence suggests that epidermal signals instruct the immune system in SLE, but whether epidermal IFNκ alone is sufficient to drive lupus phenotypes has not been investigated.
Benjamin Klein   +14 more
wiley   +1 more source

Correlation of Random Urine Protein Creatinine (P-C) Ratio with 24-Hour Protein Urine in Lupus Nephritis Patients

open access: yesIndonesian Journal of Rheumatology, 2018
Background : Systemic lupus erythematosus (SLE) is a systemic autoimmune disease involving multiple organs including kidney and known as lupus nephritis (LN). Lupus nephritis has a poor prognosis after a 10-years onset, more than 25% will be ended by end
Y H Aini   +3 more
doaj   +1 more source

Correlation of Random Urine Protein Creatinine (P-C) Ratio with 24-Hour Protein Urine in Lupus Nephritis Patients [PDF]

open access: yes, 2016
Background : Systemic lupus erythematosus (SLE) is a systemic autoimmune disease involving multiple organs including kidney and known as lupus nephritis (LN). Lupus nephritis has a poor prognosis after a 10-years onset, more than 25% will be ended by end
Aini, Y. H. (Y)   +3 more
core  

Questions about Chemokine and Chemokine Receptor Antagonism in Renal Inflammation [PDF]

open access: yes, 2010
Chemokines remain attractive therapeutic targets for modulating inflammatory diseases in all areas of medicine including acute and chronic kidney disease.
Anders, Hans-Joachim   +2 more
core   +1 more source

Reactive Oxygen Species–Induced Modifications of Fibrin Clots as a Link Between Immune Responses and Atherothrombosis in Systemic Lupus Erythematosus

open access: yesArthritis &Rheumatology, EarlyView.
Objective Cardiovascular events are major determinants of morbidity and mortality in systemic lupus erythematosus (SLE), particularly in patients with renal involvement. Although oxidative stress has been implicated in driving vascular and renal damage in SLE, the specific mechanisms remain unclear.
Matteo Becatti   +13 more
wiley   +1 more source

Biomarkers in biological fluids and their potential use as indicators of lupus nephritis in individuals with systemic lupus erythematous

open access: yesRevista Colombiana de Nefrología, 2014
Lupus nephritis is one of the most severe manifestations of systemic lupus erythematous. Renal involvement in patients with systemic lupus erythematous is an important cause of morbidity and mortality. The pathogenesis of lupus nephritis involve multiple
Lisandro Pacheco-Lugo   +2 more
doaj   +1 more source

A Case of Henoch-Schonlein Purpura Associated with Rotavirus Infection in an Elderly Asian Male and Review of the Literature. [PDF]

open access: yes, 2017
BACKGROUND Henoch-Schönlein purpura (HSP), a small vessel vasculitis mediated by deposition of immune-complexes containing IgA in the skin, gut, and glomeruli, often presents with abdominal pain, purpuric rash in the lower extremities and buttocks, joint
Adderley   +13 more
core   +2 more sources

Sensitivity and Specificity of Pathologic Findings to Diagnose Lupus Nephritis.

open access: yesAmerican Society of Nephrology. Clinical Journal, 2019
BACKGROUND AND OBJECTIVES In 2012, the Systemic Lupus International Collaborating Clinics proposed that lupus nephritis, in the presence of positive ANA or anti-dsDNA antibody, is sufficient to diagnose SLE.
Satoru Kudose   +5 more
semanticscholar   +1 more source

Sjögren Disease—B Cells at the Brink: From Autoimmunity to Lymphomagenesis and the Rise of Novel B Cell–Targeted Therapies

open access: yesArthritis &Rheumatology, EarlyView.
Sjögren disease (SjD) is a common systemic autoimmune disorder characterized by inflammation of the exocrine glands, resulting in dryness. Patients frequently exhibit extraglandular manifestations affecting various organ systems. To date, there are no US Food and Drug Administration (FDA)‐approved disease‐modifying therapies for SjD. In this review, we
Rachael A. Gordon, Sara S. McCoy
wiley   +1 more source

Home - About - Disclaimer - Privacy